Dr. Barbara Haertl is an experienced scientist who specializes in process development and manufacturing in the field of oncolytic viral therapy. Barbara has more than 12 years of industry experience that spans oncolytic virotherapy, translational oncology, and biological drug development. She joined StemVAC GmbH/Calidi Biotherapeutics in 2016 and has focused on Vaccinia Virus-based process development and manufacturing activities for virus, cell, and combination products.
Prior to joining StemVAC GmbH, Barbara led translational product development studies for oncolytic virus cancer theranostics at Genelux GmbH – a clinical-stage oncolytic virus therapy company.
Dr. Haertl received her Ph.D. in Virology on studying Adenovirus from the University of Regensburg, Department for Medical Microbiology and Hygiene, Germany
